C-reactive protein in psoriasis [11]

British Journal of Dermatology

Volumn 158, Issue 2, 2008, Pages 417-419

  Sergeant, A ^a   Makrygeorgou, A ^a   Chan, W C ^a   Thorrat, A ^a   Burden, D ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

C reactive protein; High sensitivity C reactive protein; Psoriasis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ANALYSIS OF VARIANCE; BLOOD SAMPLING; DISEASE DURATION; DISEASE SEVERITY; ERYTHRODERMA; HUMAN; INFLAMMATION; LETTER; LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; RANK SUM TEST; SCORING SYSTEM; ULTRAVIOLET B RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RISK ASSESSMENT;

EID: 38349145331     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08334.x     Document Type: Letter

References (6)

1. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004 150 : 917 28.
2. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004 18 : 180 3.
3. National Institute for Health and Clinical Excellence. TA103. Psoriasis, Efalizumab and Etanercept - Guidance. Available at: http://www.nice.org.uk/ nicemedia/pdf/word/TA103guidanceword.doc (accessed 14 November 2007).
4. Sitton NG, Dixon JS, Bird HA, Wright V. Serum biochemistry in rheumatoid arthritis, seronegative arthropathies, osteoarthritis, SLE and normal subjects. Br J Rheumatol 1987 26 : 131 5.
5. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 41.
6. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001 103 : 1813 18.